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Thiazole moiety at C-3 position based quinolone derivatives 
have been synthesized from the starting material aniline and its 
derivatives. All synthesized compounds in this series have been tested 
for in vitro antibacterial activity against E. coli (ETEC), S. typhi,  
P. aeruginosa and S. aureus. All synthesized compound have been 
tested with reference drugs viz., norfloxacin and ciprofloxacin. 
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antibiotics 
Several potentially useful drugs based on quinolone 
system have been developed in recent years. Quinolone 
derivatives have great medicinal properties as to use 
antibacterial1-3, antifungal4, antiviral5, anti-tuberculosis6 
and antitumor7,8. 
Heterocycles containing nitrogen and sulfur have 
been under investigation for a long time because of their 
important medicinal properties. Among the wide range 
of heterocycles, one of the important molecules is 
thiazole. It played an important role in medicinal 
chemistry. A survey of literature has shown that 
compounds bearing thiazole nucleus especially 2-amino 
thiazole possess a broad range of biological activities. 
Thiazoles and their derivatives have been reported to 
possess chemotherapeutic action9, antibacterial10,11, 
antifungal12, anti-tuberculosis13, anti-inflammatory 
activities14 and are also an important class of 
heterocyclic compounds. Hence, they have been 
employed to develop pharmaceutically important hybrid 
molecules with combination of quinolone for effective 
therapeutical treatment. Here quinolone derivatives 
incorporated with 2-amino thiazole moieties at C-3 of 
quinolone derivatives have been synthesized. 
 
Results and Discussion 
The synthesized compounds have been screened 
in vitro for their antibacterial activity against E. coli, 
S. typhi, P. aeruginosa and S. aureus bacteria. 
Biological results of these compounds are compared 
with marketed reference drugs norfloxacin  
and ciprofloxacin. Biological data reveals that  
N-1H, 4-dihydro-4-oxoquinoline-3- (1-oxo-N-thiazolyl) 
-amide derivatives were unfortunately found to be 
inactive as antibacterials against screening microbes 
(E. coli, S. aureus, S. typhi and P. aeruginosa), as shown 
in Table I. 
 
Material and Methods 
Preparation of substituted-1, 4-dihydro-4-oxo-
quinoline-3-{1-oxo-N-(2-thiazolyl}-amide derivatives is 
described in Scheme I. Substituted-1, 4-dihydro-4-
oxoquinoline-3-carboxylic acid ethyl ester derivatives15 
4a-e was treated with 2-aminothiazole 5 in high boiling 
solvent diphenyl ether at 190-200°C for 1 h to give 
substituted-1, 4-dihydro-4-oxoquinoline-3-{1-oxo-N- 
(2-thiazolyl}-amide derivatives 6a-e respectively in 
>85% yield (Scheme I). 
 
Experimental Section 
Spectral data were recorded as follows: IR Spectra 
was run on a Perkin-Elmer and Shimadzu 8201 PC, FT 
Infrared spectrophotometer (νmax in cm−1). Mass spectra 
were recorded on Jeol SX-102 (FAB). NMR spectra 
have been recorded on Bruker Avance 400 and Bruker 
DRX-300 (1H NMR) and chemical shifts (δ in ppm) 
were reported relative to the solvent peak (CHCl3 in 
CDCl3 at δ 7.23, and DMSO in DMSO-d6 at δ 2.49) or 
TMS. Signals were designated as follows: s, singlet; bs, 
broad signal; d, doublet; t, triplet; m, multiplet. Melting 
points were determined by open capillary method and 
Table I — Minimum inhibitory concentration of synthesized 
compounds 
S. No. Compd Minimum Inhibitory Concentration (MIC) µg/mL 
E. coli 
(ETEC) 
S. typhi P. aeruginosa S. aureus 
1 6a 0.000 0.000 0.000 0.000 
2 6b 0.000 0.000 0.000 0.000 
3 6c 0.000 0.000 0.000 0.000 
4 6d 0.000 0.000 0.000 0.000 
5 6e 0.000 0.000 0.000 0.000 
6 Nor. 0.0625 0.25 0.0625 0.0625 
7 Cip. 0. 0625 0.0625 0.0625 0.0625 
Nor. = norfloxacin, Cip. = ciprofloxacin. 
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are uncorrected. All reagents were of commercial grade 
and used as received without further purification unless 
otherwise specified. Dry DMF and anhydrous potassium 
carbonate was used wherever required. Reagent grade 
solvents were used in all other cases unless otherwise 
specified. Organic solutions were dried over anhydrous 
Na2SO4 and concentrated with a Buchi rotary evaporator 
at low pressure. 
 
General procedure for the preparation of  
1,4-dihydro-4-oxoquinoline-3-{1-oxo-N-(2-thiazolyl)}-
amide derivatives, 6a-e 
The compound substituted-1,4-dihydro-4-
oxoquinoline-3-carboxylic acid ethyl ester 4a-e 
(0.01 mol) and 2-aminothiazole 5 (0.01 mol) was mixed 
with diphenyl ether (10 mL). The mixture was heated at 
190-200°C for 1 h. The mixture was cooled to RT, and 
hexane (10 mL) was added under stirring for 15 min at 
RT. The resulting mixture was filtered and washed with 
more and more hexane. The crude solid was purified by 
recrystallization from DMF. Homogeneity of the 
compound was checked on silica gel TLC plates. TLC 
was run in chloroform-methanol (9:1) as eluent. 
 
Spectral data 
Preparation of 4-oxo-1, 4-dihydroquinoline-3-
{1-oxo-N- (2-thiazolyl}-amide, 6a: Yield: 90%. 
m.p.298°C. FT-IR (KBr): 3221 (NH Str.), 3079 (Ar-
H), 1654 (>CO, amide), 1618 cm−1 (>CO, ketone); 
1H NMR (300 MHz, DMSO-d6): δ 13.70 (s, 1H, 
CONH), 12.48 (s, 1H, H-1), 8.93 (d, 1H, NCH), 8.35 
(d, 1H, SCH), 7.95 (s, 1H, H-2), 7.86 (d, 1H, H-5), 
7.78 (d, 1H, H-8), 7.59 (dd, 1H, H-6), 7.39 (dd, 1H, 
H-7); 13C NMR (75 MHz, DMSO-d6): δ 176.32  
(CO, amide), 162.37 (CO, ketone), 157.19, 144.67, 
139.08, 137.98, 129.01, 125.78, 125.70, 125.50, 
119.37, 114.00, 108.39; HRMS: Calcd for 
C13H9N3O2: m/z 271.2900. Found: 271.2899. Anal. 
Calcd for C13H9N3O2S: C, 57.56; H, 3.34; N, 15.49. 
Found: C, 57.52; H, 3.31; N, 15.41%. 
 
Preparation of 6-fluoro-4-oxo-1, 4-dihy 
droquinoline-3-{1-oxo-N- (2-thiazolyl}-amide, 6b: 
Yield: 88%. m.p. >320°C;FTIR (KBr): 3238 (NH 
Str.), 3087 (Ar-H), 1654 (>CO, amide), 1618 cm−1 
(>CO, ketone); 1H NMR (300 MHz, DMSO-d6):  
δ 13.50 (s, 1H, CONH), 13.06 (s, 1H, H-1), 8.89  
(s, 1H, NCH), 7.93 (d, 1H, SCH), 7.80 (s, 1H, H-2), 
7.70 (s, 1H, H-5), 7.50 (d, 1H, H-7), 7.24 (d, 1H, H-8); 
13C NMR (75 MHz, DMSO-d6): δ 175.42  
(CO, amide), 162.15 (CO, ketone) 157.11, 144.57, 
137.97, 135.87, 127.17, 122.35, 122.24, 121.93, 
114.05, 109.67, 107.93; HRMS: Calcd for 
C13H8FN3O2S: m/z 289.2749. Found: 289.2758. Anal. 
Calcd for C13H8FN3O2S: C, 53.97; H, 2.78; N, 14.52. 
Found: C, 53.92; H, 2.73; N, 14.48%. 
 
 
Scheme I — Synthesis of quinolone-thiazole 6a-e derivatives 
 
NOTES 
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Preparation of 6-chloro-4-oxo-1, 4-dihy 
droquinoline-3-{1-oxo-N- (2-thiazolyl}-amide, 6c: 
Yield: 87%. m.p. >330°C. FT-IR (KBr): 3226 (-NH 
amide), 3074 (Ar-H), 1640 cm−1 (>CO, amide); 
1H NMR (300 MHz, DMSO-d6): δ 13.46 (s, 1H, 
CONH), 12.31 (s, 1H, H-1), 8.87 (d, 1H, NCH), 8.15 
(d, 1H, SCH), 7.92 (s, 1H, H-2), 7.76 (s, 1H, H-5), 
7.49 (d, 1H, H-7), 7.36 (d, 1H, H-8); 13C NMR 
(75 MHz, DMSO-d6): δ 175.04 (CO, amide), 162.06 
(CO, ketone) 157.11, 145.13, 138.05, 137.95, 126.89, 
121.95, 121.61, 121.11, 114.03, 110.61, 108.68; 
HRMS: Calcd for C13H8ClN3O2S: m/z 305.7312. 
Found: 305.7361. Anal. Calcd for C13H8ClN3O2S: C, 
51.07; H, 2.63; N, 13.74. Found: C, 51.02; H, 2.59; N, 
13.69%. 
Preparation of 7-chloro-4-oxo-1, 4-dihy 
droquinoline-3-{1-oxo-N- (2-thiazolyl}-amide, 6d: 
Yield: 88%. m.p. >360°C. FT-IR (KBr): 3251 (-NH 
amide), 3081 (Ar-H), 1641 cm−1 (>CO, amide); 
1H NMR (300 MHz, DMSO-d6): δ 13.53 (s, 1H, 
CONH), 8.98 (d, 1H, NCH), 8.35 (d, 1H, SCH), 7.95 
(s, 1H, H-2), 7.83 (s, 1H, H-8), 7.61 (d, 1H, H-6), 
7.53 (d, 1H, H-5); 13C NMR (75 MHz, DMSO-d6):  
δ 174.95 (CO, amide), 162.29 (CO, ketone) 157.27, 
144.57, 138.89, 137.15, 127.23, 122.25, 122.16, 
121.98, 114.17, 111.25, 108.19; HRMS: Calcd for 
C13H8ClN3O2S: m/z 305.7274. Found: 305.7292. 
Anal. Calcd for C13H8ClN3O2S: C, 51.07; H, 2.63; N, 
13.74. Found: C, 51.00; H, 2.60; N, 13.68%. 
Preparation of 7-chloro-6-fluoro-4-oxo-1,4-dihy 
droquinoline-3-{1-oxo-N- (2-thiazolyl}-amide, 6e: 
Yield: 86%. m.p. >360°C. FT-IR (KBr): 3233 (-NH 
amide), 3057 (Ar-H), 1671 (>CO, amide), 1612 cm−1 
(>CO, ketone); 1H NMR (300 MHz, DMSO-d6):  
δ 13.44 (s, 1H, CONH), 8.95 (d, 1H, NCH), 8.12  
(d, 1H, SCH), 7.96 (s, 1H, H-2), 7.52 (d, 1H, H-5), 
7.27 (d, 1H, H-8); 13C NMR (75 MHz, DMSO-d6):  
δ 175.01 (CO, amide), 161.90 (CO, ketone), 157.03, 
145.44, 138.00, 136.12, 126.00, 125.92, 121.66, 
114.18, 111.81, 111.51, 108.38; HRMS: Calcd for 
C13H7ClFN3O2S: m/z 323.7263. Found: 323.7278. 
Anal. Calcd for C13H7ClFN3O2S: C, 48.23; H, 2.17; 
N, 12.98. Found: C, 48.17; H, 2.14; N, 12.94%. 
 
Acknowledgements 
This work was financially supported by the 
University Grants Commission (UGC), Grant no  
31-128/2005 SR. The authors gratefully acknowledge 
the UGC, New Delhi and World Bank Sponsored 
MHRD project TEQIP-III for financial support and 
Sophisticated Analytical Instrument Facility (SAIF), 
CSIR-Central Drug Research Institute, Lucknow for 
providing spectral data on payment basis. The authors 
are also thankful to BioGenics, Research and Training 
Centre in Biotechnology, Hubli, Karnataka for 
providing antibacterial assays to generate MIC data on 
payment basis. 
 
References 
1 Emmerson A M & Jones A M, J Antimicrob Chemother, 51 
(2003) 13. 
2 Hooper D C, Clin Infect Dis, 30 (2000) 243. 
3 Ambrose P G, Owens R C J, Quintiliani R & Nightingale C 
H, Conn Med, 61 (1997) 269. 
4 Kerns German N, Kaatzan G W & Wei P, Eur J Med Chem, 
(2008)1 
5 Crucinai G, Fravolini A, Cecchtti V, Filipponi E, Tabarrini 
O, Palu G, Del PupL & Parolin C, Abstr, C-M5 (1996) 71. 
6 Davies S, Sparham P D & Spencer R C, J Med Chem, 38 
(1995) 2974. 
7 Li L, Wang H K, Kuo S C, Wu T S, Mauger A, Lin C M, 
Hamel E & Lee K H, J Med Chem, 37 (1994) 3400. 
8 Chun M W, Olmstead K K, Choi Y S, Lee C O, Lee C K, 
Kim J H & Lee J, Bioorg Med Chem Lett, 7 (1997) 789. 
9 Liebig H, Pfetzing H & Grafe A, Arzneim-Forsch, 24 (1974) 
887. 
10 Ulusoy N, Kiraz M & Kucukbasmaci O, Monat Chem, 133 
(2002) 1305. 
11 Kaplancikli Z A, Zitouni G T, Revial G & Guven K, Arch 
Pharm Res, 27 (2004) 1081. 
12 Pathak R B, Jahan B & Bahel S C, Bokin Bobai, 9 (1981) 
477. 
13 Sytnik K M, Bylov I Y & Kovalenko S N, Zh Org Farm 
Khim, 1 (2003) 71. 
14 Holla B, Malini K, Rao B, Sarojini B & Kumari N,  
Eur J Med Chem, 38 (2003) 313. 
15 Koga H, Itoh A, Murayama S, Suzue S & Irikura T, J Med 
Chem, 23 (1980) 1358. 
 
